Æterna Zentaris Obtains Positive Opinion For Perifosine From EMA
Æterna Zentaris’ partner and licensee for perifosine in the North American market, Keryx Biopharmaceuticals, has already received orphan drug designation for perifosine for the treatment of multiple myeloma
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.